Bristol’s Breyanzi best in class; Opdivo+Yervoy longest survival ever lung & melanoma

ASCO 2022 saw publication of new data for Bristol's CD-19 CAR-T Breyanzi (liso cel) in large cell non-Hodgkin’s lymphoma, along with unprecedented 5 year long-term overall survival benefit for Opdivo plus Yervoy in first line lung cancer